201 related articles for article (PubMed ID: 10575056)
1. Mechanisms modifying atherosclerotic disease - from lipids to vascular biology.
Weissberg P
Atherosclerosis; 1999 Sep; 147 Suppl 1():S3-10. PubMed ID: 10575056
[TBL] [Abstract][Full Text] [Related]
2. [The promise of statins].
Capurso A
Ital Heart J Suppl; 2001 Mar; 2(3):224-9. PubMed ID: 11307780
[TBL] [Abstract][Full Text] [Related]
3. Macrophages and atherosclerotic plaque stability.
Libby P; Geng YJ; Aikawa M; Schoenbeck U; Mach F; Clinton SK; Sukhova GK; Lee RT
Curr Opin Lipidol; 1996 Oct; 7(5):330-5. PubMed ID: 8937525
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic plaque passivation for the reduction of recurrent cardiac events in acute coronary syndromes.
Monroe VS; Kerensky RA; Rivera E; Smith KM; Pepine CJ
J Am Coll Cardiol; 2003 Feb; 41(4 Suppl S):23S-30S. PubMed ID: 12644337
[TBL] [Abstract][Full Text] [Related]
5. Statins: the new aspirin?
Veillard NR; Mach F
Cell Mol Life Sci; 2002 Nov; 59(11):1771-86. PubMed ID: 12530513
[TBL] [Abstract][Full Text] [Related]
6. [New information on the pathophysiology of atherosclerosis].
Reiner Z; Tedeschi-Reiner E
Lijec Vjesn; 2001; 123(1-2):26-31. PubMed ID: 11379194
[TBL] [Abstract][Full Text] [Related]
7. Contribution of the WHHL rabbit, an animal model of familial hypercholesterolemia, to elucidation of the anti-atherosclerotic effects of statins.
Shiomi M; Koike T; Ito T
Atherosclerosis; 2013 Nov; 231(1):39-47. PubMed ID: 24125408
[TBL] [Abstract][Full Text] [Related]
8. Apoptosis in atherosclerosis: beneficial or detrimental?
Kockx MM; Herman AG
Cardiovasc Res; 2000 Feb; 45(3):736-46. PubMed ID: 10728396
[TBL] [Abstract][Full Text] [Related]
9. What have we learned about the biology of atherosclerosis? The role of inflammation.
Libby P
Am J Cardiol; 2001 Oct; 88(7B):3J-6J. PubMed ID: 11595192
[TBL] [Abstract][Full Text] [Related]
10. Stabilisation of atherosclerotic plaques. Position paper of the European Society of Cardiology (ESC) Working Group on atherosclerosis and vascular biology.
Ylä-Herttuala S; Bentzon JF; Daemen M; Falk E; Garcia-Garcia HM; Herrmann J; Hoefer I; Jukema JW; Krams R; Kwak BR; Marx N; Naruszewicz M; Newby A; Pasterkamp G; Serruys PW; Waltenberger J; Weber C; Tokgözoglu L
Thromb Haemost; 2011 Jul; 106(1):1-19. PubMed ID: 21670845
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of acute coronary syndromes and the potential role of statins.
Dupuis J
Atheroscler Suppl; 2001 Feb; 2(1):9-14. PubMed ID: 11286155
[TBL] [Abstract][Full Text] [Related]
12. New insights into plaque stabilisation by lipid lowering.
Libby P; Aikawa M
Drugs; 1998; 56 Suppl 1():9-13; discussion 33. PubMed ID: 9740536
[TBL] [Abstract][Full Text] [Related]
13. Non-lipid-lowering effects of statins on atherosclerosis.
Rosenson RS
Curr Cardiol Rep; 1999 Sep; 1(3):225-32. PubMed ID: 10980846
[TBL] [Abstract][Full Text] [Related]
14. [Statins and antiplatelet agents: complementary mechanisms of action at the coronary artery level].
Chapman J
Am J Cardiovasc Drugs; 2007; 7 Spec No 1():5-8. PubMed ID: 19839181
[TBL] [Abstract][Full Text] [Related]
15. Atherosclerotic plaque rupture and thrombosis. Evolving concepts.
Fuster V; Stein B; Ambrose JA; Badimon L; Badimon JJ; Chesebro JH
Circulation; 1990 Sep; 82(3 Suppl):II47-59. PubMed ID: 2203564
[TBL] [Abstract][Full Text] [Related]
16. [Statins: possibly more than just lowering of the lipid level].
Visseren FL; Lansberg PJ; Erkelens DW; Kastelein JJ
Ned Tijdschr Geneeskd; 2000 Feb; 144(7):316-21. PubMed ID: 10707742
[TBL] [Abstract][Full Text] [Related]
17. Role of apoptosis in atherosclerosis and its therapeutic implications.
Stoneman VE; Bennett MR
Clin Sci (Lond); 2004 Oct; 107(4):343-54. PubMed ID: 15230690
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
19. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology.
van der Wal AC; Becker AE; van der Loos CM; Das PK
Circulation; 1994 Jan; 89(1):36-44. PubMed ID: 8281670
[TBL] [Abstract][Full Text] [Related]
20. Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end-points.
Kinlay S; Selwyn AP; Delagrange D; Creager MA; Libby P; Ganz P
Curr Opin Lipidol; 1996 Dec; 7(6):389-97. PubMed ID: 9117144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
